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Abstract
Background—3-hydroxypalmitoleoyl-carnitine (C16:1-OH) was recently reported to be elevated 
in acylcarnitine profile of propionic acidemia (PA) or methylmalonic acidemia (MMA) patients 
during expanded newborn screening (NBS). High levels of C16:1-OH, combined with other 
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hydroxylated long chain acylcarnitines are related to long-chain 3-hydroxyacyl-CoA 
dehydrogenase deficiency (LCHADD).
Methods—The acylcarnitine profile of two LCHADD patients was evaluated using liquid 
chromatography-tandem mass spectrometric method. A specific retention time was reported for 
each hydroxylated long chain acylcarnitine. The same method was applied to some neonatal dried 
blood spots (DBS) from PA and MMA patients presenting abnormal C16:1-OH concentrations.
Results—The final retention time of the peak corresponding to C16:1-OH in LCHADD patients 
differed from those in MMA and PA patients. Heptadecanoylcarnitine (C17) has been identified as 
the novel biomarker specific for PA and MMA patients through high resolution mass spectrometry 
(Orbitrap) experiments. We found that 21 out of 23 neonates (22 MMA, and 1PA) diagnosed 
through the Tuscany region NBS program had significantly higher levels of C17 compared to 
levels detected in controls.
Twenty-three maternal deficiencies (21 vitamin B12 deficiency, 1 homocystinuria and 1 gastrin 
deficiency) and 82 false positive for propionylcarnitine (C3) results were also analyzed.
Conclusions—This paper reports on the characterization of a novel biomarker able to detect 
propionate disorders during expanded newborn screening (NBS). The use of this new biomarker 
may improve the analytical performances of NBS programs especially in laboratories where 
second tier tests are not performed.
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Introduction
Propionic and methylmalonic acidemias are inborn errors of propionate metabolism that 
originate from the incorrect catabolism of isoleucine, valine, threonine, methionine, odd-
chain fatty acids and cholesterol (1).
Propionic acidemia (PA, OMIM 606054) is a result of defective activity of propionyl-CoA 
carboxylase, an enzyme that catalyzes the conversion of propionyl-CoA to methylmalonyl-
CoA. It is caused by mutation in the genes PCCA (OMIM 232000) and PCCB (OMIM 
232050) which encode for alpha and beta subunits of propionyl-CoA carboxylase, 
respectively (2).
Methylmalonic acidemia (MMA) is a genetically heterogeneous disorder caused by either 
mutations in the MUT gene encoding for the methylmalonyl-CoA mutase (OMIM 609058) 
(and causing partial, mut (−), or complete mut 0, enzyme deficiency) or a defect in the 
transport or biosynthesis of MUT coenzyme adenosylcobalamin (AdoCbl). AdoCbl defect 
are classified according to complementation group in CblA, caused by mutation in the 
MMAAgene (OMIM 607481), and CblB, caused by mutation in the MMAB gene (OMIM 
607568).
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Combined methylmalonic acidemia and homocystinuria may be seen in complementation 
groups CblC (OMIM 277400), CblD (OMIM 277410), and CblF (OMIM 277380). 
Methylmalonic acidemia may be due to a mutation in the gene CD320 (OMIM 606475) 
encoding the transcobalamin receptor TCBLR or a mutation in the methylmalonyl-CoA 
epimerase gene (OMIM 608419) (3, 4).
The clinical manifestations of these disorders include vomiting, lethargy, coma, intermittent 
ketoacidosis, hyperglycinemia, neutropenia, thrombocytopenia, hyperammonemia and 
hypoglycemia. The severity of clinical and biochemical phenotype is associated with 
different genes and/or mutations involved. Diagnosis and treatment of patients with 
MMA/PA can prevent acute acidosis and metabolic decompensation (5). Expanded newborn 
screening (NBS) for metabolic diseases by tandem mass spectrometry allows pre-
symptomatic detection and early treatment of affected newborns with MMA or PA.
The Acylcarnitine profile of dried blood spot (DBS) samples from newborns with propionate 
metabolism defect usually shows increased levels of propionylcarnitine (C3). This analyte is 
used worldwide as a marker for both defects, but it is not specific and causes large numbers 
of false-positive results (6). In order to improve the specificity of the test, some authors have 
suggested including the calculation of metabolite ratios C3/C2, C3/C16, C3/Met in the 
newborn screening panel and to use specific algorithms (7).
In a previous published paper we proposed a second-tier test (2nd TT) able to reveal the 
presence of 3-OH-propionic or methylmalonic acids on the same dried blood spot. The 
application of this 2nd TT in all newborns with C3 above the cut off levels has potentially 
allowed a positive predictive value close to 100% to be achieved (8).
Some newborn screening laboratories are still not performing 2nd TT when C3 is outside the 
normal ranges; they are therefore forced to keep a relatively high C3 cut off to avoid an 
unsustainable number of false positive results.
While laboratories performing 2nd TT for C3 have minimized false-positive rate, the risk of 
false negative results remains because 2nd TT is only applied to initial out-of-range 
screening results.
Methylmalonic acidemia combined with homocystinuria (CblC defect) can be missed during 
newborn screening because of the initial low levels of C3 (9, 10) as well as maternal vitamin 
B12 deficiencies (11).
Several papers have recently reported that in many patients affected by PA or MMA, 
newborn screening results showed an increased concentration of 3-hydroxyhexadecenoyl (or 
3-hydroxypalmitoleoyl) -carnitine (C16:1-OH) in addition to elevated C3 and related ratios, 
even if no correlation with the diseases’ pathogenesis was recognized at that time (7, 11).
C16:1-OH and other hydroxylated long chain acylcarnitines are well-known markers of 
long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) and/or trifunctional 
protein (TFP) deficiency.
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In this paper we provide evidence that the new biomarker involved in PA and MMA is 
heptadecanoylcarnitine C17 and not C16:1-OH.
Finally, we investigate the diagnostic value of this new biomarker for improving the 
sensitivity and the specificity of NBS for propionate metabolism disorders.
MATERIALS AND METHODS
Retrospective study population
DBS samples are routinely collected from all neonates born in the Italian regions of Tuscany 
and Umbria (about 40000/year) for NBS (12). In order to have the highest possible 
sensitivity, a 2nd TT for free methylmalonic and 3-OH-propionic acid has been performed 
since 2007 if first screen C3 value is ≥ 3.3 µmol/L. The cutoff value (98th percentile of our 
population, based on 50000 NBS tests) corresponds to approximately 2 % of 2nd TT per 
year.
Twenty-three affected neonates were evaluated in this study: 22 with heterogeneous genetic 
disorders of MMA, one with PA. In addition, a retrospective revaluation was performed on 
23 newborns with MMA due to maternal deficiency (21 vitamin B12 deficiencies, one 
homocystinuria and one cobalamin malabsorption due to gastric atrophy).
Eighty-two false-positives (C3 ≥ 3.3 µmol/L, and negative at 2nd TT) detected during the 
same period were also evaluated for comparative analysis.
Five controls for each of the index cases (n=635) were taken randomly and blinded in the 
same analytic batch. We proceeded in the same way for the cases with MMA due to 
maternal deficiency (n=138). Low birth weight infants (<1800g), newborns receiving 
parenteral nutrition or a blood transfusion before newborn screening test were excluded.
All experiments were conducted in compliance with Institutional Review Board guidelines 
of the Meyer Children’s Hospital Ethic Committee.
Standards
C17 and C17-D3 were purchased from GiottoBiotech (Florence, Italy). Stock solutions of 
chemical and labelled standards at 100 mmol/L were prepared in methanol and stored at- 
20°C. Working solutions were prepared daily from stock solutions at final concentration of 
0.01 µmol/L. Other reagents, such as HPLC-grade water, formic acid, and methanol, were 
purchased from Panreac (Barcelona, Spain). Labelled acylcarnitine internal standards were 
purchased from Cambridge Isotope Laboratories (Andover, MA, USA); a stock solution was 
made in methanol. The standard acylcarnitine concentrations were in the range 7.6–152 
mmol/L.
LC-MS/MS method for C16:1-OH isobaric compound separation
Two DBS (about 6.4–6.8 µL whole blood) for each sample were extracted with 200 µL of 
methanol for 25 min at room temperature. The extract was then transferred to a clear 1.5 mL 
vial for LC-MS/MS analysis.
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The data were obtained using an API 4000 triple quadrupole mass spectrometer (AB 
SCIEX, Toronto, Canada) equipped with Turbo Ion Spray source and operating in MRM 
positive ion mode. The ion spray voltage was set to 5200 V, the gas 1 and gas 2 were set 
both at 30 and 45 respectively and the temperature was set to 450 °C.
Two MS/MS experiments were performed: an MRM experiment to monitor the transition 
414.5>85.1 m/z specific for C16:1-OH acylcarnitine, and a precursor of 85 m/z scan 
experiment to analyze all acylcarnitines in the range of 300–500 Da.
The chromatographic separation was achieved using an Agilent 1260 Infinity HPLC 
capillary system (Agilent Technologies, Waldbronn, Germany), operating in gradient mode, 
coupled with a thermostated autosampler and fully controlled by Analyst Software (Version 
1.5.2).
The chromatographic run was performed by using a Synergi Polar column, 4 µm, 150×2 mm 
(Phenomenex, Torrance, CA) at a flow rate of 200 µL/min; the eluate was directed into the 
ESI source without splitting. The mobile phase was composed by water +0.1 % formic acid 
(phase A, pH 2.8) and methanol + 0.1% formic acid (phase B).
Separation was achieved using a linear gradient from 90% to 30% (phase A) over 50 
minutes; the conditions were maintained for 15 minutes, after which the mobile phase was 
returned to the starting conditions within 0.5 minutes and re-equilibrated for 9.5 minutes. 
The total run time was 75 minutes. The injection volume was 20 µL, and the autosampler 
temperature was maintained at 4°C throughout the analyses.
Orbitrap experiments
A Nexera liquid chromatograph (Shimadzu, Kyoto, Japan) coupled to a Thermo Q Exactive 
mass spectrometer (Thermo Fisher Scientific, Waltham, USA) was used for liquid 
chromatography–mass spectrometry (LC-MS) measurements. The mass spectrometer, 
operated in positive electrospray (ESI+) mode, was equipped with a heated ESI source 
(HESI-II, at 200°C) and the ionization voltage was set to 3.5 kV at a capillary temperature of 
320°C. The scan event cycle used a full scan mass spectrum (100–1000 Da) at a resolving 
power of 140.000 (at m/z 200) and three corresponding data dependent MS/MS events 
acquired at a resolving power of 70.000 using HCD. The three most intense ions detected 
during full scan MS triggered data dependent scanning. Data dependent scanning was 
performed with and without the use of a precursor ion list. The MS/MS activation 
parameters were an isolation width of 4 Da, stepped collision energies of 20, 30, and 35 V 
and an activation time of 30 milliseconds. The mass accuracy was determined from an 
external calibration performed the same day. The software Xcalibur 3.0.63 (Thermo Fisher 
Scientific, Waltham, USA) was used for data acquisition.
C17
The fragmentation patterns of C17 and C17-D3 were recorded by infusing standard solutions 
(0.1 mg/L) at 10 µL/min, directly in the ESI source of the API 4000. Three specific MRM 
transitions (414.4>85 m/z, 414.4>355.1 m/z, 414.4>253.1 m/z; 417.4>85 m/z, 417.4>358.1 
m/z, 417.4>256.1 m/z, for C17 and C17-D3 respectively) were recorded with experimentally 
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optimized declustering, collision energy and collision exit potential values (42V, 25V and 
29V, respectively).
Statistical analysis
We used the STATA 13 (T Stat s.r.l., College Station, Texas) for statistical analysis and 
descriptive statistics (means, standard deviation) to describe participants’ main variables.
ANOVA and Bartlett’s test were used to analyze the difference between the three groups 
(MMA/PA cases, negative controls and false-positives C3 ≥ 3.3 µmol/L).
To assess and compare the diagnostic accuracy of the measured biomarkers (C3, C17, 
C3/C0, C3/C2, C3/C4, C3/C16, C3/Met, methionine) we calculated sensitivity, specificity, 
area under the receiver operating characteristic (ROC) curve (AUC). We chose the cut-off 
that maximized the percentage of correctly classified and, in case of equal AUC, sensitivity.
Finally, we have defined a testing strategy combining information from the biomarkers.
When appropriate, confidence intervals (CI) were calculated using likelihood (13). Level of 
significance was set at 5% two sided.
Results
In order to understand the significance of the increased concentration of C16:1-OH observed 
on DBS of patients with propionate metabolism defect, we performed a chromatographic 
separation of the extracts obtained from neonatal DBS of controls, MMA, PA and LCHADD 
patients.
Two MS/MS experiments were monitored during the chromatographic separation: a MRM 
for the transition 414.5>85.1 m/z and a precursor ion scan of 85 m/z, enabling the 
measurement of all acylcarnitines in the range 300–500 m/z.
The total ion current of the MRM experiments revealed a practically flat baseline in control 
samples (two small peaks were detectable at about 60.6 and 61.9 minutes). The profile 
obtained from LCHADD samples showed one intense peak at retention time (RT) 52.6 
minutes (peak 1) and two smaller peaks (about 60.8 and 62.0 minutes, peak 2 and peak 3, 
respectively) while PA and MMA samples reveals only the two peaks at 60.6 and 62.0 
minutes (Figure 1). High resolution LC-Orbitrap MS and MS/MS experiments have 
demonstrated that peak 1 corresponds to C16:1-OH (as expected in LCHADD patient, data 
not shown) while peaks 2 and 3 correspond to acylcarnitine C17 (Figure S1). Considering 
that the pKa of the carboxyl group of acylcarnitines is 3.8 (14), dissociated and 
undissociated isoforms were present (the elution mixture measured pH 3.25 at 
approximately RT 60 minutes).
Low- and high-resolution MS/MS spectra of C17 chemical standards and related RT 
corresponded to those found in PA and MMA patients.
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Considering that NBS laboratories usually measure the metabolite C16:1-OH/C17 in 
precursor ion scan mode by using labelled C16 as internal standard, and considering that 
their concentration and MS signal is significantly different and potentially not accurate, we 
decided to add new specific MRMs using D3-C17 at 0.01 µmol/L. A precursor ion scan of 
85 m/z can be also used by adding D3-C17 as internal standard.
Biomarker concentrations from neonatal DBS were reported for patients (Table 1) and 
maternal deficiencies (Table 2).
Statistical analysis
Box-plot of cases, controls and false-positives show the distribution of biomarker 
concentrations within each group (Figure S2). The group means (ANOVA) and variances 
(Bartlett-test) were significantly different from each other for all biomarkers except 
methionine (Met) (Table 3). For this reason we decided to exclude the biomarker Met from 
the diagnostic analysis.
Table 4 shows the results of diagnostic analysis. The best diagnostic performance for 
metabolism defects (MMA and PA) was observed by C17 with cut-off set up to 0.092 
µmol/L (corresponding to the 99.8 percentile) 91.30% sensitivity (95% CI 72.0%; 98.9%); 
99.84% specificity (95% CI 99.1%; 100%) and AUC = 0.956 (95% CI 0.897; 1.000); C3 
with cut-off set up to 5.633 µmol/L (corresponding to the 99.93 percentile) 65.22% 
sensitivity (95% CI 42.7%; 83.6%); 99.51% specificity (95% CI 98.6%; 99.9%) and AUC = 
0.824 (95% CI 0.724; 0.923) and C3/C16 ratio with cut-off set up to 2.338 (corresponding to 
the 99.4 percentile) 65.22% sensitivity (95% CI 42.7%; 83.6%); 98.69% specificity (95% CI 
97.4%; 99.4%) and AUC = 0.820 (95% CI 0.720; 0.919).
Based on these results we explored a combination of biomarkers (Table 5): the best strategy 
was a parallel testing of C17 and C3 (tests are declared positive if C17 ≥ 0.092 µmol/L or C3 
≥ 5.633 µmol/L) with AUC = 0.997; 95% CI 0.994; 1.000; 100% sensitivity (95% CI 85.2%; 
100%), 99.35% specificity (95% CI 98.3%; 99.8%).
Discussion
In this paper we have demonstrated that a new metabolite, C17 acylcarnitine, is suggestive 
for the diagnosis of propionate metabolism defects (MMA and PA) and should be 
considered an important biomarker. The presence of large amounts of odd-numbered long-
chain fatty acids in adipose tissue (from 8% to 10% of total fatty acids vs 1% in normal 
controls) during fetal life in newborns suffering of propionate metabolism defects has been 
largely reported from Wendel and collaborators (15–17). During periods of acute catabolism, 
such as in the early days of life, the mobilization and the oxidation of odd-chain fatty acids 
from adipose tissue leads to the production of extensive amounts of toxic propionyl-CoA in 
the mitochondria. Fatty acid synthase catalyzes the synthesis of palmitate from acetyl-CoA 
and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids. The 
excess of propionyl-CoA in the mitochondria could be considered to be the likely cause of 
the production of a small percentage of heptadecanoic fatty acid. This acid, like most other 
carboxylic acids, can be activated by acyl-CoA synthases to form heptadecanoyl-CoA, 
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which cannot be oxidized to carbon dioxide in mammalian cells. As a result, heptadecanoyl-
CoA accumulates in cells and becomes a substrate for several acyl-CoA transferases. These 
reactions generate heptadecanoic-conjugates and among them C17 detectable by newborn 
screening tests. The Tuscany region’s newborn screening program began in 2004; out of 
more than 500000 newborns screened, 23 affected by inborn errors of propionate 
metabolism have been identified. The study of C17 neonatal concentration in this group 
showed 21 measurements higher than cutoff values, confirming the high prognostic 
significance of the biomarker. It should be noted that this biomarker would have failed in the 
identification of two newborns with MMA mut (−) phenotype (and one newborn affected by 
transcobalamin II deficiency; disorder not included in our NBS panel). In our experience the 
sensitivity of C17 can be considered comparable to or higher than C3/C2 ratio (20/23 correct 
identifications, plus transcobalamin II deficiency). Considering our cut-off levels, other 
ratios presented less sensitivity (Table 1).
In 2007, after one CblC false negative result, we developed a 2nd TT for the detection of 3-
OH propionic acid and methylmalonic acid on DBS (8), reducing the upper C3 cutoff value 
to 98th percentile of our population, corresponding to 3.3 µmol/L. The previous C3 cutoff 
5.65 µmol/L corresponded to 99.95th percentile. Eight affected newborns (three mut (−) and 
five CblC) tested after 2007 presented with a C3 concentration lower than 5.65 µmol/L. 
Furthermore, one CblC patient was subjected to 2nd TT during this study because he 
presented with a high C17 level (0.14 µmol/L) even with normal C3 concentration (3.05 
µmol/L).
Statistical analysis demonstrated that C17 is able to distinguish negative newborn specimen 
results (controls + false negative) from positive ones better than other parameters previously 
used in our NBS program (Figure S2A). It should be noted that C17 alone seems to be the 
biomarker with the best correct classification as compared to other biomarkers. For NBS 
laboratories that are still not performing 2nd TT, the inclusion of C17 as specific biomarker 
could significantly improve the sensitivity of the first tier test.
Otherwise we consider the combination of first and second-tier testing for many metabolic 
disorders to be the best working practice for achieving the most benefit from NBS programs 
(18). In our daily practice we have modified our NBS protocol as reported in Figure S3.
Different considerations must be done for maternal vitamin B12 deficiencies. Poor nutrition, 
such as a vegetarian diet during pregnancy, can lead to vitamin B12 deficiency causing 
serious problems in newborn metabolism. Some babies whose mothers had vitamin B12 
deficiency show a MMA and homocysteine accumulation (19). A severe maternal vitamin 
B12 deficiency in breast-fed infants can cause failure to thrive, developmental regression, 
anemia and nerve-related disorders. Prolonged metabolic decompensation can lead to severe 
lethargy progressing slowly to coma and irreversible neurological damage (20).
Early identification of these cases can make life-saving interventions prior to clinical 
manifestation possible (21). However, vitamin B12 supplementation should be always 
recommended in vegetarian/vegan mothers during pregnancy as well as while breastfeeding.
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In our NBS program we were able to identify 19 maternal vitamin B12 deficiencies, one 
maternal homocystinuria and one maternal gastrin deficiency because our C3 cut-off. The 
power of C17 alone for the detection of maternal disorders (without 2nd TT) should be 
considered only moderately important, as it was capable of identifying only 10/23 cases 
(sensitivity 43.48%) (Table 2). On the other hand, two additional vitamin B12 deficiencies 
were discovered during this study through 2nd TT because they presented C17 at 0.1 µmol/L 
and 0.13 µmol/L upon NBS test even if the C3 values were normal (2.61 and 3.22 µmol/L, 
respectively). Moreover the possibility of detecting a maternal deficiency is consistently low 
if 2nd TT is not performed and the corresponding C3 cut-off is maintained high to reduce the 
C3-related false positive rate.
Conclusions
The results of this study strongly suggest the evaluation of C17 as primary biomarker 
(together with C3 and ratios) for propionate metabolism defects, especially in NBS 
laboratories where 2nd TT is still not available.
The use of 2nd TT is a worldwide NBS good practice parameter that greatly improves the 
specificity of the first screening results. However, 2nd TT depends on the results of the first 
tier test and the final sensitivity will be influenced by the cut off value of the primary 
marker. While this study has some limitations (exclusion of low birth weight infants <1800g 
and newborns receiving parenteral nutrition or a blood transfusion before newborn screening 
test), in our experience the evaluation of the new biomarker C17 improved sensitivity 
suggesting the utility of performing the 2nd TT even when the primary marker C3 falls 
within normal limits (two maternal vitamin B12 deficiencies and 1 CblC). However, a false-
negative result cannot be excluded when both biomarkers (C3 and C17) are lower than the 
cut offs and 2nd TT is not performed.
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LCHADD long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
DBS dried blood spot
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2nd TT second-tier test
NBS newborn screening
MRM multiple reaction monitoring
HCD higher energy collisional dissociation
ESI electrospray ionization
RT retention time
ROC receiver operating characteristic
AUC area under the curve
CI confidence intervals
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The LC-MS/MS profile obtained from LCHADD neonatal samples.
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Table 3
ANOVA and Bartlett’s test results for all biomarkers.
ANOVA Bartlett's test
F(2) P-value Χ2(2) P-value
C3 573.450 <0.001 692.750 <0.001
C17 454.720 <0.001 459.696 <0.001
Met 2.410 0.090 0.437 0.804
C3/C0 151.560 <0.001 70.620 <0.001
C3/C4 239.530 <0.001 362.769 <0.001
C3/C2 23.680 <0.001 266.749 <0.001
C3/C16 68.430 <0.001 190<0.001 <0.001
C3/Met 74.250 <0.001 240<0.001 <0.001
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Table 4
Cut-off, sensitivity, specificity and AUC for biomarkers of MMA/PA metabolism defects. 95% confidence 
intervals in parentheses
Cut-off Sensitivity Specificity AUC
C3 ≥ 5.633
65.22% 99.51% 0.824
(42.7%; 83.6%) (98.6%; 99.9%) (0.724; 0.923)
C17 ≥ 0.092
91.30% 99.84% 0.956
(72.0%; 98.9%) (99.1%; 100%) (0.897; 1.000)
C3/C0 ≥ 0.339
52.17% 99.02% 0.756
(30.6%; 73.2%) (97.9%; 99.6%) (0.652; 0.860)
C3/C4 ≥ 29.376
52.17% 99.35% 0.758
(30.6%; 73.2%) (98.3%; 99.8%) (0.653; 0.862)
C3/C2 ≥ 1.120
4.35% 99.84% 0.521
(0.11%; 21.9%) (99.1%; 100%) (0.478; 0.564)
C3/C16 ≥ 2.338
65.22% 98.69% 0.820
(42.7%; 83.6%) (97.4%; 99.4%) (0.720; 0.919)
C3/Met ≥ 0.504
56.52% 99.84% 0.782
(34.5%; 76.8%) (99.1%; 100%) (0.678; 0.885)
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Table 5
Sensitivity, specificity and AUC for a combination of tests for MMA/PA. 95% confidence intervals in 
parentheses
Sensitivity Specificity AUC
C17≥0.092 or C3≥5.633 100% 99.30% 0.997
(85.2%; 100%) (98.3%; 99.8%) (0.994; 1.000)
C17≥0.092 or C3/C16 ≥2.338 91.30% 98.50% 0.949
(72%; 98.9%) (97.2%; 99.3%) (0.890; 1.000)
C17≥0.092 or C3≥5.633 or C3/C16≥2.338 100% 98.50% 0.993
(85.2%; 100%) (97.2%; 99.3%) (0.988; 0.997)
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